The answer, first. Both are graded early human — some human data exists for each, and it is early and partial rather than pivotal. Neither is approved. The two are usually discussed as a pair rather than as alternatives, but on evidence quality they currently sit at the same grade, and neither has a finished record.
Side by side
The same two axes this site applies to every compound, with nothing added for the comparison.
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Clinical evidence | early human | early human |
| Community adoption | high | high |
| Category | growth hormone | growth hormone |
| Our summary | A GHRH analog engineered for a longer half-life, sold with or without the DAC modification. Early human studies showed it raises growth hormone and IGF-1, but development stopped and it was never approved. | A selective ghrelin-receptor agonist and one of the most-sold GH secretagogues. Early human data exists from a development program that was discontinued — it never reached approval. |
| Full file | CJC-1295 → | Ipamorelin → |
What actually separates them
Three differences that hold up against the published record, rather than against marketing.
What neither can tell you
- What is in the vial. A comparison between molecules says nothing about the contents of a specific lot. Only a certificate of analysis does, and most cover fewer measures than buyers assume — start with how to read a COA.
- A dose. This site describes what published protocols used and never prescribes.
- Which is right for you. That is a clinical question about an individual, and nothing here is medical advice.
Questions we get
Is CJC-1295 or ipamorelin better?
On this site both are graded early human on clinical evidence, meaning some human data exists for each and it is early or partial rather than pivotal. Neither is approved. At the same grade, the published record does not establish one as better than the other.
Are they meant to be used together?
They are commonly discussed and sold together. This site describes what published protocols used and does not prescribe, and it is worth being explicit that early or partial human data on each compound separately is not evidence about the combination.
What would move either grade?
Completed, published, randomised human trials with a stated endpoint. Early-stage human data is exactly the kind that changes when larger trials run, which is why the grade is held where it is.